United States: Addressing Breach Of Method-Of-Use Patents By Generics

The U.S. Court of Appeals for the Federal Circuit on April 16, 2012, in Bayer Schering Pharma AG v. Sandoz Inc., Nos. 2011-1143, -1228 (Yasmin), affirmed a district court's holding that as a matter of law, generic drug makers could not infringe patent claims reciting a method of use of a U.S. Food and Drug Administration (FDA)-approved drug where the FDA had not approved the drug for the claimed uses, and where the FDA-approved labeling did not indicate instructions or intent to encourage the claimed use.

Yasmin is a drug Bayer produces and markets under FDA approval as an oral contraceptive. The asserted patent did not claim the drug Yasmin itself or the use of Yasmin solely as an oral contraceptive. Rather, the patent was directed to a method of use narrowly focused on simultaneously achieving three effects in patients: an anti-androgenic effect (anti-acne), an anti-aldosterone effect (diuretic) and a contraceptive effect.

The FDA-approved label for Yasmin undisputedly indicated the drug was approved as an oral contraceptive. However, the parties disputed whether the label could also be interpreted to indicate that Yasmin should be used as claimed, i.e., as an anti-acne and diuretic drug as well as a contraceptive.

Watson Pharmaceuticals Inc. and Sandoz argued that Yasmin was approved only for contraceptive use, that their abbreviated new drug applications (ANDAs) necessarily included an "indications and usage" section which provided information related only to contraceptive use and that such contraceptive-only indications were not covered by Bayer's patent.

The majority opinion identified the critical question in this case to be whether the FDA affirmatively found Yasmin to be safe and effective for the additional purposes of inducing anti-acne and diuretic effects in a patient with a specific need for all three of those effects.

It was not enough that the FDA was aware that Yasmin could cause the patented effects, or even that the FDA approved marketing materials promoting the use of Yasmin to achieve those effects.

The majority identified the U.S. Court of Appeals for the Federal Circuit's previous decisions in Warner-Lambert Co. v. Apotex Corp., 316 F.3d 1348 (Fed. Cir. 2003), and Allergan Inc. v. Alcon Labs. Inc., 324 F.3d 1322 (Fed. Cir. 2003), as informing the current opinion.

In both cases, the generic drug manufacturer sought FDA approval to market either an unpatented or expired patented drug for an unpatented FDA-approved use. The court ruled in both instances in favor of the generic drug maker on the grounds that it is not infringement to market a drug for a specific use when neither the drug nor its approved use is covered by an unexpired patent.

In deciding the critical question here, the majority looked only at the drug label for the use listed in the Orange Book. More specifically, the majority looked to the "indications and usage" portion of the label. The majority observed that this portion of the label details the specific conditions that the FDA approved the drug to treat.

Although other potential effects of the drug may be described in other portions of the label, the information in those sections failed to establish that the FDA approved the drug for producing those effects in a patient who needs them.

Specifically, the "clinical pharmacology" portion of the Yasmin label mentioned that one of the two active compounds in Yasmin had anti-aldosterone effects and that preclinical studies in animals had shown it to also have anti-androgenic effects.

The majority noted that these statements did not indicate that the FDA has actually approved Yasmin for producing these effects in human patients needing them, and the label did not provide any safety or efficacy information for prescribing Yasmin for such uses.

The majority also noted that under FDA labeling regulation, only the indications and usage portion of the label reflects the FDA's approval.

According to the majority, because the FDA had not formally approved Yasmin for all three purposes claimed in the patent, as a matter of law, Bayer could not state a claim for patent infringement. The majority affirmed that the suit against Watson Pharmaceuticals and Sandoz was properly dismissed on the pleadings, before even beginning pre-trial discovery.

Federal Circuit Judge Pauline Newman dissented from the majority opinion, ascribing error to the majority's conclusion that listing some of Yasmin's properties in the clinical pharmacology section of the label, instead of the indications and usage section, removed the generic counterpart from the scope of the patent's claims.

Newman also disagreed that the label, taken in its entirety, failed to recommend or suggest to a physician that Yasmin was safe and effective for inducing the claimed combination of effects in patients in need thereof. In the dissent's view, the portion of the FDA label in which a product's properties are described is irrelevant to whether the patent is infringed by sale or use of the product.

Furthermore, the dissent contended that, as a matter of pleading its case in its complaint, Bayer had sufficiently alleged that an "intended use" for Yasmin— as approved by the FDA— was the simultaneous treatment of all three effects. Accordingly, the dissent believed that Bayer was entitled to an opportunity to further litigate its case.

Bottom Line

The Federal Circuit's decision that the generic drug makers could not infringe the asserted patent was based on the single approved indication for the drug. The FDA's approval of the single indication, to the exclusion of other uses claimed in the asserted patent, was established by the FDA-approved label taken as a whole —with particular emphasis on the "indications and usage" section of the label and notwithstanding statements found in other sections of the label that failed to show that the FDA approved the drug for those claimed uses.

Vincent Capuano, the chair of Duane Morris' Hatch-Waxman IP practice group, is a partner in Duane Morris' Boston office. Matthew Mousley is an associate in the firm's Philadelphia office, and Kristina Caggiano is an associate in the Washington, D.C., office. Michele Kliem is a patent agent in the firm's Atlanta office.

This article is for general information and does not include full legal analysis of the matters presented. It should not be construed or relied upon as legal advice or legal opinion on any specific facts or circumstances. The description of the results of any specific case or transaction contained herein does not mean or suggest that similar results can or could be obtained in any other matter. Each legal matter should be considered to be unique and subject to varying results. The invitation to contact the authors or attorneys in our firm is not a solicitation to provide professional services and should not be construed as a statement as to any availability to perform legal services in any jurisdiction in which such attorney is not permitted to practice.

Duane Morris LLP, a full-service law firm with more than 700 attorneys in 24 offices in the United States and internationally, offers innovative solutions to the legal and business challenges presented by today's evolving global markets. Duane Morris LLP, a full-service law firm with more than 700 attorneys in 24 offices in the United States and internationally, offers innovative solutions to the legal and business challenges presented by today's evolving global markets. The Duane Morris Institute provides training workshops for HR professionals, in-house counsel, benefits administrators and senior managers.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions